1. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. (10th April 2018) Authors: Mehnert, Janice M.; Silk, Ann W.; Lee, J. H.; Dudek, Liesel; Jeong, Byeong‐Seon; Li, Jiadong; Schenkel, Jason M.; Sadimin, Evita; Kane, Michael; Lin, Hongxia; Shih, Weichung J.; Zloza, Andrew; Chen, Suzie; Goydos, James S. Journal: Pigment cell & melanoma research Issue: Volume 31:Number 4(2018) Page Start: 534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗